Massachusetts Financial Services Co. MA Has $12.12 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Massachusetts Financial Services Co. MA raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 2.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 405,870 shares of the company’s stock after acquiring an additional 10,731 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Kymera Therapeutics were worth $12,115,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in Kymera Therapeutics in the fourth quarter valued at approximately $78,000. Comerica Bank grew its stake in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares during the period. Ameritas Investment Partners Inc. grew its stake in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after acquiring an additional 295 shares during the period. Virtu Financial LLC acquired a new stake in Kymera Therapeutics in the first quarter valued at approximately $207,000. Finally, Keudell Morrison Wealth Management grew its stake in Kymera Therapeutics by 7.2% in the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after acquiring an additional 480 shares during the period.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of research reports. Morgan Stanley raised their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 14th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Oppenheimer reaffirmed an “outperform” rating and set a $52.00 target price on shares of Kymera Therapeutics in a research report on Wednesday, July 10th. B. Riley lifted their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Finally, Wells Fargo & Company lifted their target price on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.67.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the sale, the director now directly owns 723,246 shares in the company, valued at $27,635,229.66. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Kymera Therapeutics news, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total value of $1,060,272.45. Following the sale, the insider now directly owns 95,470 shares in the company, valued at $4,373,480.70. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bruce Booth sold 453,960 shares of Kymera Therapeutics stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the transaction, the director now owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The disclosure for this sale can be found here. Insiders have sold a total of 495,605 shares of company stock worth $19,303,364 over the last ninety days. 15.82% of the stock is currently owned by company insiders.

Kymera Therapeutics Trading Up 1.6 %

Shares of Kymera Therapeutics stock opened at $49.79 on Friday. The business’s fifty day simple moving average is $45.28 and its 200 day simple moving average is $39.07. The firm has a market capitalization of $3.06 billion, a P/E ratio of -19.84 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12 month low of $9.60 and a 12 month high of $50.69.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. The business had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. Kymera Therapeutics’s quarterly revenue was up 55.2% compared to the same quarter last year. During the same period last year, the company posted ($0.67) earnings per share. Analysts predict that Kymera Therapeutics, Inc. will post -2.87 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.